<DOC>
	<DOCNO>NCT02431364</DOCNO>
	<brief_summary>This randomize , double-blind , sequential , dose-escalation , Phase 1 trial evaluate safety tolerability verdinexor . Verdinexor placebo give day 1 3 healthy adult subject .</brief_summary>
	<brief_title>Trial Safety Tolerability Oral Verdinexor ( KPT-335 ) Healthy Adults</brief_title>
	<detailed_description>This randomize , double-blind , sequential , dose-escalation , Phase 1 trial evaluate safety tolerability verdinexor . Verdinexor placebo give day 1 3 healthy adult subject . Cohorts 8 subject ( 6 active , 2 placebo ) sequentially administer verdinexor placebo ( one dose Day 1 one dose Day 3 ) use dose-escalation scheme . A conservative , sequential , dose-escalation strategy employ decrease escalation increment use .</detailed_description>
	<criteria>Subjects must good health determine investigator , base medical history , ECG , physical examination , safety laboratory test screen . Subjects must identify nonsmoker screen visit ( nonsmoker define individual abstain smoke least 1 year prior screen visit â‰¤ 15 pack year history lifetime cigarette use ) . A urine cotinine test perform screening time clinic checkin prior study drug treatment . The subject surgical medical condition potentially may alter absorption , metabolism , excretion study drug gastrectomy , Crohn 's disease , liver disease . The subject history clinically significant allergy . Hay fever allow unless active require treatment within previous 2 month . Presence chronic condition ( ) clinical historical evidence recent exacerbation , information suggest noncontrol condition ( ) . History alcohol abuse drug addiction within 12 month screen visit . Any subject active cataract medical history cataract .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>KPT-335</keyword>
	<keyword>Verdinexor</keyword>
	<keyword>Karyopharm</keyword>
	<keyword>First-in-Human</keyword>
	<keyword>Adult Subjects</keyword>
</DOC>